Epstein-Barr virus infection after unrelated cord blood transplantation: Reactivation or reinfection? [1]

International Journal of Hematology

Volumn 85, Issue 3, 2007, Pages 267-269

  Kawa, Keisei ^a,b   Sawada, Akihisa ^a   Koyama, Maho ^a   Inoue, Masami ^a  

^a RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^b NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; VINCRISTINE;

ADULT; CASE REPORT; CAUSE OF DEATH; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE COURSE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EPSTEIN BARR VIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNOTHERAPY; LABORATORY DIAGNOSIS; LETTER; LOW DRUG DOSE; REINFECTION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION;

ADULT; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIRUS LATENCY;

EID: 34247566614     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.07014     Document Type: Letter

References (13)

1. Kawabata Y, Hirokawa M, Saitoh Y, et al. Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia. Int J Hematol. 2006;84:445-448.
2. Kawa K. Hemophagocytic syndrome-treatment strategies according to classification and scoring system. In: Education Program Book of the 67th Annual Meeting of the Japanese Society of Hematology and the 47th Annual Meeting of the Japanese Society of Clinical Hematology. Tokyo, Japan; 2005:72-75.
3. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549-1555.
4. Ohga S, Kanaya Y, Maki H, et al. Epstein-Barr virus-associated lymphoproliferative disease after a cord blood transplant for Diamond-Blackfan anemia. Bone Marrow Transplant. 2000;25:209-212.
5. Cohen J, Gandhi M, Naik P, et al. Increased incident of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol. 2005;129:229-239.
6. Agbalika F, Larghero J, Esperou H, et al. Epstein-Barr virus early-antigen antibodies before allogeneic haematopoietic stem cell transplantation as a marker of risk of post-transplant lymphoproliferative disorders. Br J Haematol. 2006;136:305-308.
7. Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated cord blood transplantation. Blood. 2006;108:2874-2880.
8. Gratama JW, Oosterveer MAP, Zwaan FE, et al. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implication for sites of viral latency. Proc Natl Acad Sci U S A. 1988;85:8693-8696.
9. Qu L, Xu S, Rowe D, Triulzi D. Efficacy of Epstein-Barr virus removed by leukoreduction of red blood cells. Transfusion. 2005;45:591-595.
10. Meijer E, Spijkers S, Moschatsis S, et al. Active Epstein-Barr virus infection after allogeneic stem cell transplantation: re-infection or reactivation? Transpl Infect Dis. 2005;7:4-10.
11. Yagita M, Iwakura H, Kishimoto T, et al. Successful allogeneic stem cell transplantation from an unrelated donor for aggressive Epstein-Barr virus-associated clonal T-cell proliferation with hemophagocytosis. Int J Hematol. 2001;74:451-454.
12. Gratama JW, Lennette ET, Lonnqvist B, et al. Detection of multiple Epstein-Barr viral strains in allogeneic bone marrow transplant recipients. J Med Virol. 1992;37:39-47.
13. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol. 2002;44:259-272.